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Abstract
Ovarian cancer has a poor prognosis due to intrinsic or acquired resistance to some cytotoxic drugs, raising the interest in
new DNA-binding agents such as mithramycin analogues as potential chemotherapeutic agents in gynecological cancer.
Using a genome-wide approach, we have analyzed gene expression in A2780 human ovarian carcinoma cells treated with
the novel mithramycin analogue DIG-MSK (demycarosyl-3D-b-D-digitoxosyl-mithramycin SK) that binds to C+G-rich DNA
sequences. Nanomolar concentrations of DIG-MSK abrogated the expression of genes involved in a variety of cell processes
including transcription regulation and tumor development, which resulted in cell death. Some of those genes have been
associated with cell proliferation and poor prognosis in ovarian cancer. Sp1 transcription factor regulated most of the genes
that were down-regulated by the drug, as well as the up-regulation of other genes mainly involved in response to cell stress.
The effect of DIG-MSK in the control of gene expression by other transcription factors was also explored. Some of them,
such as CREB, E2F and EGR1, also recognize C/G-rich regions in gene promoters, which encompass potential DIG-MSK
binding sites. DIG-MSK affected several biological processes and molecular functions related to transcription and its cellular
regulation in A2780 cells, including transcription factor activity. This new compound might be a promising drug for the
treatment of ovarian cancer.
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Introduction
Ovarian cancer is an important cause of morbidity and
mortality worldwide and the main cause of death among
gynecological cancers [1,2]. Surgery followed by platinum-taxane
chemotherapy is the standard treatment for ovarian cancer [3].
Despite improvements in complete clinical remission and
progression-free survival, resistance to chemotherapy presents a
major problem in the treatment of ovarian cancer and a
contributing factor in cancer-associated mortality [1–3]. There-
fore, given that ovarian cancer shows a high risk of relapse, it
seems necessary to improve the efficacy of novel targeted therapies
[4].
Regulation of gene transcription is often a central point in
oncogenic signaling [5]. In ovarian cancer, an integrated genomic
analysis has been undertaken [6], and there have been intents to
assess the association between transcription, overall survival and
response to chemotherapy [7,8]. In this context, identifying
transcription factors that are involved in tumorigenesis and cancer
progression may provide us with targets for chemotherapeutic
intervention based on small compounds [5,9]. Although targeting
transcription factors and their interactions with gene promoters is
a difficult approach, it is nowadays considered an attainable goal
[5,9]. In fact, many clinically useful agents, such as the
anthracyclines doxorubicin and daunorubicin, several alkylating
agents and mithramycin A, can regulate gene expression by
binding to C+G-rich DNA sequences recognized by the Sp-family
of transcription factors, thus abrogating the transcriptional activity
of genes essential for cancer cell growth [9,10]. Ovarian cancer
cells over-express several genes that contribute to tumor develop-
ment [6,11–15]. In many cases, these genes are activated by Sp1
[16–18] and/or by other transcription factors [7], representing
potential targets for therapeutic intervention.
Mithramycin A (MTA) is an aureolic acid-type polyketide
antibiotic produced by various species of Streptomyces [19]. It has
been used in the treatment of Paget’s disease and advanced
testicular carcinoma, but it showed numerous toxic side effects
which have limited its clinical use [20]. At the molecular level, the
activity of MTA and several of its analogues has been associated
with their ability to bind to C/G-rich regions within the DNA
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minor groove [21–23], and references therein. At present, MTA is
the subject of ongoing clinical trials in Ewing sarcoma (http://
www.ClinicalTrials.gov; Identifier: NCT01610570) and lung,
esophagus and other chest cancers (http://www.ClinicalTrials.
gov; Identifier: NCT01624090), indicating a renewed interest in
this kind of compounds for clinical cancer treatment.
The genetic organization of the MTA biosynthesis gene cluster
has been studied in detail, and the MTA biosynthetic pathway
used to produce new compounds with enhanced biological
characteristics [19,21,24–26]. New mithramycin analogues bear-
ing both lower toxicity and higher biological activity are now
available, providing new possibilities for therapeutic application
[18,19,25]. MTA and its analogues tested to date can inhibit
transcription both in vivo and in vitro by interfering with protein-
DNA interactions, especially the inhibition of Sp1-dependent
transcription [17,18,27–29]. Recently, a new analogue named
DIG-MSK (demycarosyl-3D-b-D-digitoxosyl-mithramycin SK;
EC-8042) (Fig. 1) has been obtained and characterized [25].
DIG-MSK shows in vivo and in vitro antitumor activities similar
to other novel analogues like the structurally related MSK, but
DIG-MSK is 10-fold less toxic in vivo than MTA and 25% less
toxic than MSK [25]. Remarkably, the single maximum tolerated
dose of DIG-MSK in mice is the highest among the mithramycin
analogues [25]. DIG-MSK inhibits the growth of HCT-116
human colon carcinoma cells, where it inhibits the interaction
between transcription factors and DNA [29]. Moreover, the
in vivo evaluation of DIG-MSK antitumor activity by hollow fiber
assays indicates that it is a promising antitumor drug against
ovarian cancer, among other neoplasms [25].
Using A2780 human ovarian carcinoma cells, we sought to
characterize the effects of the mithramycin analogue DIG-MSK
on transcription through a genome-wide analysis of changes in
gene expression. As expected, we observed this compound reduced
the expression of a variety of genes, many of which have been
related with ovarian cancer progression, but also up-regulates the
expression of other genes, consistent with the stress response that
chemotherapeutic drugs can produce in treated cells. We postulate
that the effects of DIG-MSK on gene transcription are mainly due
to interference with the binding of Sp1 to its putative binding sites
in gene promoters, yet we also observed that other transcription
factors were modulated by the drug in their binding to gene
promoters, in keeping with our previous observations in colon
carcinoma cells [29]. Besides, several biological processes and
molecular functions related to transcription and its cellular
regulation, including transcription factor activity, were significant-
ly influenced by DIG-MSK in A2780 cells.
Materials and Methods
Cell culture and drug treatments
A2780 human ovarian carcinoma cells were growth in RPMI
1640 medium (Life Technologies) supplemented with 10% fetal
bovine serum (Life Technologies), 100 U/ml penicillin, 100 mg/
ml streptomycin and 2 mM sodium pyruvate at 37uC in a
humidified atmosphere with 5% CO2.
Demycarosil-3D-b-D-digitoxosyl mithramycin SK (DIG-MSK;
EC-8042) (Fig. 1) was isolated and purified (HPLC$97%) from
the producer Streptomyces species as described elsewhere [25].
Stocks of DIG-MSK were prepared as 1 mM solutions in sterile
150 mM NaCl, maintained at 220uC, and brought to the final
concentrations just before use. Exponentially growing cells
subcultured at a density of 2.56104 cells/ml were grown in the
presence of several concentrations of DIG-MSK in the nanomolar
range.
Assessment of cell proliferation and viable cell number
The capacity of DIG-MSK to interfere with the growth of
A2780 cells proliferation was determined by the MTT assay using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (Sigma, St.
Louis, MO) as described elsewhere [30]. Briefly, cells subcultured
at a density of 2.56104 cells/ml were incubated with a nanomolar
range of drug concentrations at 37uC for 72 h, and MTT was
added to each culture. Viable cell number was determined at
different intervals based on the exclusion of Trypan blue dye and a
hemocytometer.
RNA preparation
Cell lysates were prepared from A2780 human ovarian
carcinoma cells treated in triplicate with 8 nM or 80 nM DIG-
MSK –see Results about how these drug concentrations were
selected–, and from untreated cells. RNA was isolated from those
independent biological replicates by using the Ultraspec RNA
reagent (Biotecx) following the manufacturer’s recommendations.
RNA was digested with RNAse-free DNAse I (Roche Diagnostics)
in the presence of RNasin (Promega), phenol extracted and
precipitated, and the pellets were dissolved in RNAse-free water.
RNA was quantified using a NanoDrop spectrophotometer, and
the integrity of total RNA monitored with an Agilent 2100
Bioanalyzer. All samples showed a RIN higher than 7.
Microarray analysis
Total RNAs (0.2 mg) from each sample (biological replicates)
were amplified, labeled and hybridized to a SurePrint G3 Human
Gene Expression Microarray (Agilent, ID 028004). RNA labeling
was performed with the Low Input Quick Amp Labeling kit
(Agilent) following the manufacturer’s protocol. Oligoarray
hybridization buffer (In Situ Hybridization Kit Plus (Agilent))
was added afterwards, and samples applied to microarrays
enclosed in Agilent SureHyb-enabled hybridization chambers.
Images of the microarrays were acquired using a G2505C Scanner
(Agilent). Background subtraction and locally weighted scatterplot
smoothing (lowess) normalization were performed using the
Feature Extraction Software v. 10.7.3.1 (Agilent). Arrays were
processed at Bioarray SL (Elche, Spain). All statistical and
differential expression analyses were carried out with an empirical
Bayes approach on linear models using the Limma package from
Bioconductor (http://www.bioconductor.org/). Gene expression
was considered up- or down-regulated when it changed $1.5-fold
Figure 1. Chemical formulae of the mithramycin analogue DIG-
MSK (demycarosyl-3D-b-D-digitoxosyl-mithramycin SK). DIG-
MSK differs from the parental mithramycin A in the side chain linked to
C-3 and the distal sugar in the trisaccharide moiety.
doi:10.1371/journal.pone.0104687.g001
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(up-regulated) or #0.67-fold (down-regulated) and statistically
significant (p,0.05). The microarray data can be accessed at the
Gene Expression Omnibus (GEO) database: http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc = GSE46926.
Validating microarray data by qRT-PCR
An aliquot of the RNA preparations from untreated and drug-
treated samples used in the microarray analysis were saved for
validation by qRT-PCR. RNAs from each experimental condition
were pulled together and analyzed in three independent quanti-
fications. First strand cDNAs were synthesized from DNAse I-
treated total RNA. The qRT-PCR reactions were performed in
triplicate in a Roche LightCycler 480, using the SYBR-Green
PCR Master Mix (Roche Diagnostics), and the primers shown in
Table S1. PCR conditions included an initial denaturation step at
95uC for 10 min, followed by 45 cycles of a denaturation step at
95uC for 15 s and an annealing/extension step at 60uC for 1 min.
A final dissociation curve was generated to verify that a single
product was amplified. Reactions in the absence of template and
in the absence of enzyme were also included as negative controls.
Fold changes between treatments were determined by the DCt
method [31], using the expression of the housekeeping GAPDH
gene for data normalization.
Gene Ontology (GO) analysis
Functional classification of the genes down-regulated upon
treatment with DIG-MSK (#0.67-fold change) in Biological
Process and Molecular Function categories was performed by
comparison with the list of all the genes studied by using
PANTHER v.7 (http://www.pantherdb.org/tools/), which uses
the binomial test for assessing statistical significance [32].
Identification of transcription factors associated to genes
affected by DIG-MSK
The Transcription Element Listening System (TELiS) [33] was
used to analyze the prevalence of transcription factor-binding
motifs, among the promoters of genes down-regulated upon
exposure to DIG-MSK. The Incidence analyses, provided by the
software, indicated genes bearing at least one binding site for a
particular transcription factor that were present in a greater
fraction of differentially expressed genes than in the sampling
frame as a whole. This binary analysis was executed online as an
exact binomial test at http://www.telis.ucla.edu/index.
php?cmd = transfac; using default parameters (promoter size ‘‘2
600’’ and stringency setting ‘‘0.9’’). Consensus sequences corre-
sponding to transcription-factor binding sites were located in the
promoter regions of the genes down-regulated by DIG-MSK
through multiple comparative analysis, and retrieved using TELiS.
Consensus transcription factor binding sites were identified
using both the JASPAR database (http://jaspar.genereg.net/cgi-
bin/jaspar_db.pl) and MatInspector 8.0 (Genomatix Software
Suite).
An enrichment analysis was performed using Enrichr [34] to
obtain an unbiased identification of whether genes down-regulated
by DIG-MSK were among those described to be up-regulated in
A2780 human carcinoma cells, thus they participate in the
characteristics of A2780 transformed state. A list consisting of
down-regulated genes (#0.67-fold, p,0.05) was uploaded at:
http://amp.pharm.mssm.edu/Enrichr, where it was compared
with the Cancer Cell Line Encyclopedia [35]. The Fisher’s exact
test, provided by Enrichr [34], was used to assess the statistical
significance of the overlap between the input list and genes
overexpressed in A2780 cells.
Hierarchical clustering of selected data
Logarithmic (log2) values of the normalized expression ratios
(treated versus untreated cells) were hierarchically clustered using
the TIGR-MeV program [36], based on the Pearson correlations.
A comparison was undertaken with the total of genes differentially
expressed by 8 and 80 nM DIG-MSK for bibliographic co-
citations, pathways and diseases (MeSH terms) in the Genomatix
Pathways System (GePS) platform included in the Genomatix
Software Suite (http://www.genomatix.de/solutions/genomatix-
software-suite.html). A set of 32 genes was selected from the genes
modulated by both 8 nM and 80 nM DIG-MSK in A2780 cells,
filtered by Diseases (MeSH) and Ovarian neoplasm by using GePS
in the Genomatix Software Suite, and for the presence of
consensus Sp1 binding sites in their promoters using TELiS
[33]. Details on the whole procedure are provided in Results.
Cell cycle analysis by flow cytometry. A2780 cells treated
with DIG-MSK and untreated, control, cells were harvested at
different periods of time, fixed with 70% ethanol, and stained with
PI (propidium iodide, Sigma) as described elsewhere [30]. Nuclei
were analyzed with a Coulter Epics-XL flow cytometer (Coulter
Corporation), using the 488 nm line of an argon laser and
standard optical emission filters.
Assessment of the mechanisms of cell death
Apoptosis was quantified and distinguished from necrosis by
using the Annexin-V-Fluos staining kit (Roche Diagnostics) and
flow cytometry in a Coulter Epics-XL flow cytometer (Beckman
Coulter).
Western analysis
Protein was extracted from A2780 cells treated with 80 nM
DIG-MSK and from untreated cells. About 20 mg of denatured
proteins were subjected to electrophoresis on SDS-polyacrylamide
gels, blotted onto Optitran BA-S85 membranes (Schleicher &
Schuell), probed with specific antibodies: p21WAF1 (Calbiochem,),
p53 (Santa Cruz), Sp1 (Santa Cruz), Sp3 (Santa Cruz), and
GAPDH (Sigma), incubated with secondary antibodies (Jackson
ImmunoResearch), and detected by chemiluminescence using the
Immobilon Western HRP Substrate (Millipore).
Chromatin immunoprecipitation (ChIP)
For chromatin immunoprecipitation (ChIP), about 107 A2780
cells either untreated or treated with 80 nM DIG-MSK for 24 h
were cross-linked with 1% formaldehyde for 10 min. After
quenching formaldehyde, cells were collected, lysed, and washed
with cold PBS. Chromatin was re-suspended in 4 ml of a buffer
consisting of 1 mM EDTA, 0.1% SDS, 10 mM Tris-HCl (pH 7.4),
containing protease inhibitors, and sonicated in a Bioruptor
(Diagenode) for 25 min to obtain 200–500 bp fragments. Cross-
linked chromatin was pre-cleared with 40 ml Dynabeads-Protein A
(Invitrogen) and then immunoprecipitated with anti-Sp1 antibody
(H-225X, Santa Cruz) in RIPA buffer (140 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 0.1% SDS, 0.1% sodium deoxycholate,
10 mM Tris-HCl (pH 8.0), and protease inhibitors) using 30 ml of
pre-blocked Dynabeads-Protein A (Invitrogen). As a negative
control, mock immunoprecipitations were carried out using rabbit
IgG (Thermo Scientific). Subsequently, cross-links were reversed
and DNA purified. qRT-PCR was performed on ChIP material
using the primers for XIAP, CRABP1, MDK, KCNMA, and a
GAPDH coding region lacking Sp1 binding sites –negative
control– shown in Table S1, and the experimental conditions
described above.
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Results
DIG-MSK inhibits the proliferation of A2780 human
ovarian carcinoma cells
Antiproliferative effects of nanomolar concentrations of DIG-
MSK on A2780 cells were evaluated after 72-h continuous
treatments (Fig. 2). From the plot in Fig. 2, we calculated the IC50
(drug concentration required to inhibit cell growth by 50%) and
IC75 values (drug concentration required to inhibit cell growth by
75%) to be 4.2560.39 nM and 7.44 60.12 nM, respectively.
Moreover, the assessment of the reduction in viable cell number
indicated that 8 nM DIG-MSK (,its IC75 at 72 h) produced
around 4% cell death at 24 h, which reached 9% in 72-h
treatments. Besides, 80 nM DIG-MSK (i.e. 10-fold the IC75
concentration measured after 72-h treatments) produced ,16%
death after 24 h and 90% after 72-h treatments.
DIG-MSK modulates gene expression in A2780 cells
We analyzed the effects of 8 and 80 nM DIG-MSK on gene
expression in A2780 human ovarian cancer cells after 24-h
treatments. These sub-lethal concentrations were selected from the
analysis of cell proliferation (Fig. 2) and viability by Trypan blue
exclusion by living cells. The supporting microarray data have
been submitted to the GEO repository (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc = GSE46926). After 24-h continuous
treatments, 8 nM DIG-MSK affected the expression of 667 genes
(1.5-fold; p,0.05), of which 160 were down-regulated (Fig. 3A). At
the same threshold, 80 nM DIG-MSK affected 4889 transcripts,
of which 2503 were down-regulated. Most of the genes showing
altered expression were down-regulated by the higher concentra-
tion. Besides, 105 genes showed down-regulated gene expression
at both concentrations (intersection in the Venn diagrams in
Fig. 3A).
We sought independent validation by qRT-PCR of the DIG-
MSK effects on gene expression. We selected 11 transcripts, that
have been reported to be challenged by DIG-MSK in a different
cancer cell type [29]. The genes analyzed by qRT-PCR are also
related to ovarian cancer [6] and/or contain putative Sp1-binding
sites. We observed substantial changes in gene expression upon
treatment with DIG-MSK (Fig. 3B), in keeping with the micro-
array data, although for some transcripts the changes were less
pronounced. Compared to control, untreated, cells those changes
were statistically significant (p,0.05). Moreover, for several genes,
differences between the effects of 8 nM and 80 nM DIG-MSK
(Fig. 3B) were highly significant (p,0.01).
Gene Ontology (GO) of genes differentially expressed
upon treatments with DIG-MSK
Table 1 classifies down-regulated genes in gene ontology (GO)
classes. This table also provides a statistical estimate of the
overrepresentation of a given functional class. DIG-MSK affected
a variety of biological routes, including genes related to
transcription regulation and metabolic cellular processes. Molec-
ular function and biological processes GO categories highlighted
the presence of genes involved in transcription regulation and
nucleic acids metabolism among the genes affected by 80 nM
DIG-MSK, which suggested that DIG-MSK alters the expression,
or binding activities, of a variety of transcriptional factors. A
similar analysis was undertaken using the results of the treatment
with 8 nM DIG-MSK (Table 2). In this case, both the number of
genes and the GO categories represented significantly (p,0.05)
were smaller, indicating a dose-dependent response to the drug.
Identification of transcription factors associated with
genes down-regulated by DIG-MSK
Given that the mithramycin analogues can be in vivo and
in vitro inhibitors of gene transcription through direct competition
with proteins for binding to DNA, we explored whether among
transcription factors that recognize gene promoters there was an
‘enrichment’ in their putative binding sites in the promoters of
down-regulated genes. This might explain the repression of gene
expression by DIG-MSK. Drug-repressed genes encompassed in
their promoters a higher proportion of binding sites for several
transcription factors than it was expected to occur by simple
chance (Table 3). Sp1 had the highest representation among the
transcription factors, in line with DIG-MSK effects on Sp1-
activated gene expression in human colon carcinoma cells [29],
and consistent with the fact that Sp1 and the mithramycin
analogues bind preferentially to C/G-rich regions in DNA. Other
transcription factors that bind to G+C sequences and participate
in the control of gene expression during cancer development, such
as EGR2, N-Myc, or E2F, were among the more represented
factors (Table 3).
Clustering and gene network analyses reveal peculiarities
in the effect of DIG-MSK on ovarian carcinoma cells
The effects of DIG-MSK on gene expression were also
examined by clustering analysis of a selected set of genes. A
hierarchical clustering, based on Pearson correlation coefficients,
of 32 differentially expressed genes is shown in Fig. 4A. This set of
genes was obtained after filtering the 278 up- and down-regulated
genes influenced by both DIG-MSK concentrations (intersections
in the Venn diagrams shown in Fig. 3A) using the Genomatix
Pathway System (GePs). GePs identified 72 genes as belonging to
‘‘Ovarian Neoplasm’’ category within ‘‘Diseases/MeSH’’. Ten of
these genes were eliminated from the following analysis because
their interaction with others was not evident. The remaining genes
were then interrogated for the presence of putative Sp1 binding
sites in their promoters using TELiS. Of them, 32 genes contained
at least one Sp1-binding consensus sequence. Therefore, the
clustered heat-map (Fig. 4A) summarizes the relationship between
drug activity at each concentration and changes in the expression
of Sp1-responsive genes relevant to ovarian cancer progression.
Figure 2. Assessment of cell proliferation. Effects of DIG-MSK on
the proliferation of A2780 human ovarian carcinoma cells after 72-h
continuous treatments. Data are mean 6 SEM from 6 independent
experiments.
doi:10.1371/journal.pone.0104687.g002
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Figure 4A offers a convenient way to visualize patterns of
dissimilarity in the effects of either drug concentration. Dendro-
grams, showing average-linkage hierarchical clustering, clustered
together several genes involved in common cellular pathways. For
the sake of comparison, we have labeled those clusters using
lowercase letters (Fig. 4A). Cluster labeled ‘‘a’’ contains genes up-
regulated by either treatment, although 80 nM DIG-MSK had a
superior enhancing effect. It encompassed genes related to various
cell functions, as cell adhesion, migration, and proliferation,
including genes involved in the control cell-cycle progression such
as CDKN1A (p21WAF), which up-regulation was consistent with
the transient halt of cells in G1 phase, described below. Most of
these up-regulated genes, listed in Table 2, also contain putative
Sp1-binding sites, although, in this case, Sp1 and DIG-MSK did
not seem to compete directly for binding to consensus promoter
sequences. Cluster ‘‘b’’ contains not only several genes that have
been described to be highly expressed in ovarian cancer, but also
DDB2, which enhanced expression would correlate with an
augmented sensitivity of ovarian cancer cells to some chemother-
apeutic agents [37]. Cluster ‘‘c’’ contains genes usually found
highly expressed in ovarian carcinoma. DIG-MSK did not
abrogate the expression of that particular group of genes. Cluster
‘‘d’’ contains genes whose expression can be induced in cellular
stress conditions, as we may expect after drug treatment. We
marked as ‘‘e’’ a single gene (GRN) that, although it clustered near
others, it was peculiar in being up-regulated by 8 nM DIG-MSK
and down-regulated by 80 nM DIG-MSK. GRN is a prognostic
marker in epithelial ovarian carcinoma [38]. The large cluster ‘‘f’’
consists of genes that underwent a dose-dependent down-
regulation. Among the genes clustered there was E2F1, a
transcription factor, as well as genes that may contribute to
tumorigenesis, including invasive ovarian carcinoma [39]. At the
very edge of cluster ‘‘f’’, but still closely related to it, KCNMA1
was labeled as ‘‘g’’ (Fig. 4A). Amplification of this gene, which was
strongly inhibited by DIG-MSK, has been associated with high
cell proliferation and poor prognosis [40].
Genes down-regulated by 80 nM DIG-MSK were uploaded
into GePS for transcriptional network analysis with sentence-level
co-cited transcription factors annotation type (Genomatix Litera-
ture Mining). This provided insights into the functional connec-
tions among genes. Four transcription factors, Sp1, BIRC5, YY1
and BRCA1, showed significant (p,0.05) enrichment in that
annotation type (Table S2). As a representative network, Fig. 4B
presents genes regulated by Sp1, in which there was a dominance
of Myc and EGR1 as pivotal nodes.
Alongside the enrichment analysis in Gene Ontology terms
described above (Tables 1 and 2), we undertook an unbiased
enrichment comparison of the list of genes down-regulated by
DIG-MSK with the list of terms available for A2780 human
ovarian carcinoma cells in the Cancer Cell Encyclopedia [35]. We
observed a strong and somewhat specific effect of DIG-MSK on
genes that were up-regulated in A2780 cells, as deemed by the
high statistical significance of the overrepresentation of DIG-
MSK-abrogated genes among those up-regulated in A2780 cells
(p= 2.45E-14; Fisher’s exact test). DIG-MSK was rather effective
in abrogating highly expressed genes in A2780 cells, which
indicates its preference for interfering with over-expressed genes.
This observation, a condition required to link its antitumor activity
to changes in gene expression, was in keeping with the finding that
other DNA-binding drugs show selective inhibiting effects on
inducible genes [41], yet in our case the effect seemed related to a
Figure 3. Analysis of gene expression in A2780 cells treated with DIG-MSK. (A) Venn diagrams representing genes affected, either up-
regulated or down-regulated in microarray analysis by treatments with 8 nM or 80 nM DIG-MSK (1.5-fold changes, p,0.05). Numbers inside the
intersections correspond to genes influenced by both drug concentrations. (B) Quantitative real-time PCR measurements of a set of genes selected
among those differentially expressed in A2780 cells treated with DIG-MSK. Compared to untreated cells, the expression of all these genes changed
significantly upon treatment (p,0.05). Histograms represent mean 6 SD from 3 independent experiments (**p,0.01, Student’s t-test comparison
between treatments with either 8 nM or 80 nM DIG-MSK).
doi:10.1371/journal.pone.0104687.g003
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direct inhibition of transcription factor binding rather than due to
downstream events.
DIG-MSK challenges Sp1-binding to gene promoters
Chromatin immunoprecipitation (ChIP) was used to measure
Sp1 occupancy at the promoters of XIAP, CRABP1, MDK and
KCNMA1 genes, which were repressed by the treatments with
80 nM DIG-MSK. All of them are involved in the development of
ovarian carcinoma [6]. A negative control was also included,
which consisted of a down-stream region of the housekeeping
GAPDH gene that lacks Sp1-binding sites. DIG-MSK decreased
Table 1. Gene Ontology (GO) categories affected by 80 nM DIG-MSK.
GO categoriesa
Agilent
Microarray
(Ref. list)
Number of
down- regulated
genes
Number of
expected
genes p-valueb
Biological process
Nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
3101 571 385.44 4.69E-21
Transcription 1879 381 233.55 3.02E-19
Transcription from RNA polymerase
II promoter
1874 380 232.93 3.44E-19
Regulation of transcription from RNA
polymerase II promoter
1493 306 185.57 1.54E-15
Primary metabolic process 6704 978 833.27 2.18E-08
Metabolic process 7060 1010 877.51 7.65E-07
System development 1167 212 145.05 6.27E-06
Establishment or maintenance
of chromatin architecture
228 58 28.34 9.58E-05
Organelle organization 253 60 31.45 5.42E-04
Developmental process 2022 317 251.32 1.96E-03
Cellular process 5081 713 631.54 1.29E-02
Molecular function
Binding 5511 915 684.98 2.71E-23
DNA binding 2041 417 253.68 4.42E-22
Nucleic acid binding 3196 581 397.24 2.60E-20
Transcription factor activity 1817 364 225.84 1.77E-17
Transcription regulator activity 1817 364 225.84 1.77E-17
Transcription cofactor activity 162 44 20.14 3.74E-04
Structural constituent of ribosome 176 5 21.88 2.34E-03
aThe GO analysis was undertaken on down-regulated genes by PANTHER 7.0.
bBinomial test.
doi:10.1371/journal.pone.0104687.t001
Table 2. Gene Ontology (GO) categories affected by 8 nM DIG-MSK.
GO categoriesa
Agilent
Microarray
(Ref. list)
Number of
Down- regulated
genes
Number of
expected genes p-valueb
Biological process
Nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process
3101 48 25.03 4.33E-4
Cell cycle 10.85 22 8.76 1.06E-02
Primary metabolic process 6704 74 54.11 7.69E-02
Molecular function
Binding 5511 75 44.48 1.17E-05
DNA binding 3196 50 25.79 1.49E-04
aThe GO analysis was undertaken on down-regulated genes by PANTHER 7.0.
bBinomial test.
doi:10.1371/journal.pone.0104687.t002
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Sp1 binding to those promoters, with a superior effect on
KCNMA1 (Fig. 5).
DIG-MSK changes the cell cycle traverse in A2780 cells
and commits cells to dying
Changes in cell cycle distribution of A2780 cells after treatments
with DIG-MSK were both concentration- and time-dependent
(Fig. 6A). Adherent and detached cells were pooled together for
cytometric analysis. A2780 cells treated with 8 nM DIG-MSK
maintained a relatively uniform phase distribution throughout the
experiment, with most cells in G1 phase, while 80 nM DIG-MSK
produced a progressive increase in the sub-G0 population.
Flow cytometry bivariate-plots of Annexin-V-fluos and PI
staining distinguished apoptosis from necrosis in A2780 cells
treated with DIG-MSK for 72 h (Fig. 6B). Cells were mainly
dying by secondary necrosis/apoptosis, which seemingly occurred
after a fast apoptotic phase. Cell death was concentration-
dependent with a higher effect of 80 nM DIG-MSK, which was
also indicated by Trypan blue staining, and the increase in the G0-
phase population (Fig. 6A).
Changes in protein levels induced by DIG-MSK are
consistent with changes in gene expression
Figure 7 presents some examples illustrating changes in protein
levels after treatment of A2780 cells with DIG-MSK. Sp1 and Sp3
protein levels were in line with the down-regulation of gene
expression by the drug. The levels of p53 increased after 24-h
treatments, decreasing afterwards (Fig. 7B), consistent with cell
arrest observed after 72 h (cf. Figs. 7A and 6A). Meanwhile,
p21WAF (CDKN1A) levels remained high. Altogether, changes in
protein levels were fully consistent with both the array/qRT-PCR
assays and the changes in the distribution of cells in the different
phases of the cell cycle (Fig. 6A).
Discussion
It is a matter of current interest whether small-molecule drugs
targeting putative transcription-factor binding sites can cause
sequential biological effects on gene expression, thus representing
practical and reliable antitumor agents [5,9]. Here, we have
presented a genome-wide analysis probing the ‘‘anti-transcription-
al’’ properties of the novel mithramycin analogue DIG-MSK,
which had shown a promising in vivo antitumor profile [25].
We observed dose-dependent differences in the number of genes
affected by DIG-MSK in A2780 cells. However, 105 genes were
down-regulated regardless of the drug concentration (Fig. 3A,
bottom panel). According to gene ontology (GO) analysis, they
mainly belong to the categories of nucleic acid binding,
transcription regulator activity and angiogenesis. Whereas 8 nM
DIG-MSK had little effect on cell viability in up to 72-h
treatments, the higher 80 nM DIG-MSK concentration, still in
the nanomolar range, showed a remarkable time-dependent
cytotoxicity, with most cells dying by apoptosis and secondary
apoptosis/necrosis (Fig. 6B). At first glance, this would indicate
that low concentrations of DIG-MSK are enough to produce
specific effects on the expression of a relatively small number of
genes, while higher concentrations affects a larger number of
genes, which, in turn, augments cell death.
Transcription is the main target for DIG-MSK, as it also for
other mithramycin analogues [10,17,29,42]. The set of genes
down-regulated by DIG-MSK comprises an extensive represen-
tation of genes that are up-regulated in untreated A2780 cells.
Although the meaning of this observation has to be contemplated
with caution, the genes overexpressed are a molecular signature of
the transformed state of A2780 cells [35], thus they represent
potential targets for therapeutic intervention in ovarian cancer [6].
The clustering analysis of a set of genes that displayed altered
expression upon treatment (Fig. 4A) indicates that putative Sp1-
binding sites, which are also potential binding sites for mithramy-
Table 3. Transcription factors whose consensus binding sequences are over-represented in the promoter region of genes down-
regulated by either 8 nM or 80 nM DIG-MSK in A2780 human ovarian carcinoma cells.
Transcription
factor 8 nM 80 nM
Consensus sequencea
Observed genes
AG: 81b Incidence
Observed genes
AG: 1262b Incidence
p-valuec p-valuec
CREB GGTGACGTAAGG 19 1.0E-03 190 1.0E-10
EGR1 ATGCGTGGGCGT // // 20 2.2E-03
EGR2 A/TTGCGTGGGCGT // // 31 1.0E-10
EGR3 ATGCGTGGGCGT 3 4.5E-02 21 1.3E-02
E2F TTTC/GGCGC 8 2.3E-02 66 2.0E-04
NF-kB GGGGACTTTCCA 18 1.4E-01 218 6,90E-03
N-Myc TCCCACGTGTCA/C/G 20 1.8E-03 198 4.0E-04
MAX AAAA/CCACGTGGTTT 13 4.9E-02 149 1.2E-02
USF GTCACGTGGC 51 1.3E-02 // //
Sp1 A/GGGGGGCGGGGCC 68 2.8E-07 816 1.0E-10
aAccording to TELiS database (http://www.telis.ucla.edu/).
bAG: Number of genes analysed.
cRanking according to the p-value (p,0.05) in incidence analyses.
//These transcription factors were not enriched in the promoters.
doi:10.1371/journal.pone.0104687.t003
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cin analogues [10,43], play a central role in both up-regulated and
down-regulated genes. Among them, GRN (granulin epithelium
precursor) is remarkable because it was up-regulated by 8 nM and
down-regulated by 80 nM DIG-MSK. GRN has been character-
ized as a prognostic marker in ovarian cancer [38].
Functional network investigation of Sp1 co-expressed genes in
DIG-MSK-treated cells highlights that Myc and EGR1 are central
nodes in the transcriptional network. They exhibited strong
interactions with other genes, including BIRC5, E2F1, and
members of the Sp-family genes (Fig. 4B and Table S2). All these
genes encode transcription factors that are potential diagnostic
biomarkers in ovarian cancer [7,44]. Their activities were
modulated by DIG-MSK (Table 3) as it also occurs in other
cancer cell lines [29]. Moreover, Myc and EGR1 are involved in
cancer development [45]. It is noteworthy that clustering gene
expression (Fig. 4A) revealed that KCNMA1 clustered with other
genes down-regulated by any DIG-MSK concentration, but it was
distinctly at the very edge of the rest of the cluster, denoting
peculiarities of gene expression in presence of the drug; its
expression was strongly inhibited by DIG-MSK. Such down-
regulation is meaningful because KCNMA1 high expression has
been associated with cell proliferation and poor prognosis in
cancer [40]. Hence, it is a candidate to be explored as target in
ovarian cancer.
Figure 4. Effects of the treatment of A2780 cells with 8 nM or 80 nM DIG-MSK on a panel of genes characterized as being related to
‘‘ovarian neoplasm’’ and containing at least one putative Sp1-binding site in the proximal promoter region. (A) Hierarchical clustering
of changes in gene expression for each treatment. Dendrograms show average-linkage hierarchical clustering based in Pearson correlation
coefficients. For the sake of comparison, lowercase letters at the right side indicate ‘‘clusters’’ with shared characteristics that are detailed in Results.
(B) Network generated by the Genomatix Pathway System (GePS) representing bibliographic relationships for Sp1 co-expressed gene profiles
(p=1.48E-03). Dashed lines indicate genes associated by co-citation, while continuous lines indicate genes associated by expert-curation. Filled
diamonds and triangles indicate the promoter of gene ‘‘B’’ (the gene with the diamond/triangle) has a corresponding experimentally validated
binding site for the transcription factor encoded by gene ‘‘A’’. Open triangles indicate that the binding of a particular transcription factor to the gene
promoter has not been described unambiguously. The sequence logo for the consensus Sp1 binding site, retrieved from JASPAR, is shown at the top
right of panel B.
doi:10.1371/journal.pone.0104687.g004
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Here, we have shown that Sp1 is involved in the regulation of
gene expression in A2780 human carcinoma cells treated with
DIG-MSK. Differences in the down-regulating effects of 8 nM
and 80 nM DIG-MSK can indicate differences in the binding
affinity of Sp1 and the mithramycins for certain consensus C/G-
rich tracts in DNA (i.e. DNA regions with high C+G content, in
which these nucleotides are arranged in peculiar sequences), like in
the KCNMA1 promoter, which may result in variations in their
concentration-dependent down-regulation (Fig. 4A). Given that
Sp1 is overexpressed in cancer cells [46], its diminished levels
upon treatments with DIG-MSK (Fig. 7) may result in tumor
remission. In this regard, DIG-MSK activity resembles that of the
structurally related MSK [17,18,29,47]. DIG-MSK shows high
activity in ovarian carcinoma cells [25] and Figs. 2 and 6B, while it
has, in general, lower toxicity [25]. ChIP experiments show that
the Sp1 occupies its binding sites in the promoters of XIAP,
CRABP1, MDK, and KCNMA1 (Fig. 5), and that DIG-MSK
decreases Sp1 binding to them with a superior effect on
Figure 5. Chromatin immunoprecipitation analysis of Sp1 binding to the promoters of XIAP, CRABP1, MDK and KCNMA1 genes in
A2780 cells in the presence/absence of 80 nM DIG-MSK. ChIP was performed using an anti-Sp1 specific antibody. A DNA fragment that does
not contain Sp1-binding sites was also immunoprecipitated as a negative control, as well as an unspecific immunoprecipitation using IgG (Mock).
DNA in both the input and in the immunoprecipitated fractions was quantified by qRT-PCR. Data (mean 6 SD from 3 independent experiments) are
shown as the enrichment of input DNA in the immunoprecipitated fractions (**p,0.01; Student’s t-test).
doi:10.1371/journal.pone.0104687.g005
Figure 6. Cell cycle distribution and mechanisms of cell death. (A) Flow cytometry analysis of the time-dependent changes in cell cycle
distribution of A2780 cells treated with either 8 nM or 80 nM DIG-MSK. Both adherent (attached) and detached (floating) cell populations were
pooled together and their distribution in the different phases of the cell cycle quantified. (B) Analysis of cell death in A2780 human ovarian carcinoma
cells treated with 8 nM or 80 nM DIG-MSK. This panel shows time-course bivariate flow cytometry analyses of control and DIG-MSK-treated cells
stained with Annexin-V-Fluos and PI. Percentages of necrosis, apoptosis and secondary necrosis/apoptosis (double staining) are indicated inside the
panels.
doi:10.1371/journal.pone.0104687.g006
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KCNMA1, a gene associated with high proliferation in cancer cells
[40]. The effect of DIG-MSK was also evident on the loading of
Sp1 on the other gene promoters (Fig. 5): XIAP whose down-
regulation can induce cell death [12], CRABP1, a gene involved
in the development of ovarian carcinoma [11], and MDK that is a
marker in ovarian cancer [14]. Besides, DIG-MSK modifies the
interaction of other factors that also recognize C+G-rich regions in
gene promoters. Some of them, including E2F1 and several
members of the Sp-family of transcription factors, have been
identified as biomarkers of ovarian cancer [44]. Among those
transcription factors, E2F1 is member of one of the nodes of the
cellular networks highly influenced by DIG-MSK (Fig. 4B).
Deregulated activity of transcription factors and the consequent
overexpression of some genes frequently occur in cancer. In this
context, MTA has been characterized a potent agent in abrogating
the transcription driven by the EWS-FLI1 oncogenic transcription
factor, a hallmark of the Ewing sarcoma family of tumors [48].
This is in keeping with the finding that binding to DNA of
transcription factors other than the members of the Sp-family can
be targeted by MTA and its analogues. Targeting over-expressed
genes in ovarian cancer, including those of transcription factors
such as Sp1 [7,44] might be an appealing strategy to abrogate
genes associated with resistance to other drugs [8]. As mentioned
above, DIG-MSK shares with other mithramycin analogues the
ability of shifting Sp1 binding, yet its better pharmacological
profile [25] suggests that this new mithramycin analogue is a
promising drug for the treatment of ovarian cancer.
Supporting Information
Table S1 Primers used for qRT-PCR.
(PDF)
Table S2 Networks affected by treatment with 8 nM and
80 nM DIG-MSK in human A2780 cells. Network anal-
ysis was performed using GePS.
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